Increased Aldosterone Levels in a Model of Type 2 Diabetes Mellitus

Abstract

Background: Aldosterone is an important mediator of cardiovascular and renal remodeling. Type II diabetes mellitus leads to renal and cardiac end organ damage. We investigated the renin-angiotensin-aldosterone system in a model of type 2 diabetes mellitus with known diabetic nephropathy and cardiac remodeling, the Zucker Diabetic Fatty rat with and without ACE-inhibition (ZDF and ZDF+ACE-I) and its control, the Zucker Lean (ZDL) rat.

Methods: Male animals were studied from an age of 7–24 weeks. At ages 7, 14, 17, 20, and 23 weeks, urinary excretion of aldosterone-glucuronide and potassium was assessed. ACE-inhibition with ramipril was started orally at week 13 (1 mg/kg/d). At the end of the study rats were sacrificed and plasma aldosterone concentration and plasma renin activity were measured. Aldosterone synthase (CYP11B2) mRNA expression in the adrenals, kidney, heart and adipose tissue was assessed by real-time PCR. Urinary albumin excretion as marker for diabetic nephropathy was measured in metabolic cages and correlated to aldosterone.

Results: Plasma aldosterone concentration and aldosterone-glucuronide was significantly elevated in ZDF rats, and significantly reduced by ACE-inhibiton. In contrast, plasma renin activity was significantly reduced in ZDF rats and normalized by ACE-inhibition. The urinary aldosterone correlated significantly to albuminuria. Adrenal CYP11B2 expression was not significantly higher in ZDF rats. CYP11B2 mRNA was not detected in the kidney, heart and adipose tissue.

Conclusion: In ZDF rats, urinary and plasma aldosterone levels were elevated despite reduced plasma renin activity. The reversible effect of ACE-inhibition shows that the up-regulation of aldosterone must be dependent of the renin-angiotensin-system in this type II diabetes model. The correlation between aldosterone and diabetic nephropathy suggests a clinical relevance of this observation.

Key words

aldosterone - diabetes type 2 - rat

References

• 1 Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet.  J Clin Endocrinol Metab. 2007;  92 4472-4475
• 2 Boudina S, Abel ED. Diabetic cardiomyopathy revisited.  Circulation. 2007;  26 ((115)) 3213-3223
• 3 Cha DR, Kang YS, Han SY, Jee YH, Han KH, Kim HK, Han JY, Kim YS. Role of aldosterone in diabetic nephropathy.  Nephrology. 2005;  10 ((Suppl)) S37
• 4 Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy.  Lancet. 1998;  352 213-219
• 5 Cronin CC, Barry D, Crowley B, Ferriss JB. Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus.  Diabet Med. 1995;  12 809-815
• 6 Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenbeg HS, Barthel A, Hauner H, MacCann SM, Scherbaum W, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors.  PNAS. 2003;  100 14211-14216
• 7 Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.  Hypertension. 2004;  43 1252-1257
• 8 Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system.  Hypertension. 2005;  45 356-362
• 9 Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, Kromer EP, Weil J. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats.  Cardiovasc Pathol. 2004;  13 11-19
• 10 Fredersdorf S, Weil J, Ulucan C, Birner C, Büttner R, Schubert T, Böger CA, Debl K, Muders F, Riegger GA, Luchner A. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.  Naunyn Schmiedebergs Arch Pharmacol. 2007;  375 95-103
• 11 Fujiwara K, Hayashi K, Matsuda H, Kubota E, Honda M, Ozawa Y, Saruta T. Altered pressure-natriuresis in obese Zucker rats.  Hypertension. 1999;  33 1470-1475
• 12 Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, Price DA, Laffel LM, Williams GH, Fisher ND. Plasma aldosterone concentration in the patient with diabetes mellitus.  Kidney Int. 2004;  65 1435-1439
• 13 Huang TH, Yang Q, Harada M, Li GQ, Yamahara J, Roufogalis BD, Li Y. Pomegranate flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: modulation of cardiac endothelin-1 and nuclear factor-kappaB pathways.  J Cardiovasc Pharmacol. 2005;  46 856-862
• 14 Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, Faire U De, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 1004-1010
• 15 Luik PT, Kerstens MN, Hoogenberg K, Navis GJ, Dullaart RP. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation.  Eur J Clin Invest. 2003;  33 787-793
• 16 Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.  Br J Pharmacol. 2001;  133 687-694
• 17 Müller J. Regulation of aldosterone biosynthesis: the end of the road?.  Clin Exp Pharmacol Physiol Suppl. 1998;  25 S79-85
• 18 Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, Chrousos G. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL).  J Steroid Biochem Mol Biol. 2005;  96 309-316
• 19 Peters B, Teubner P, Clausmeyer S, Puschner T, Maser-Gluth C, Wrede HJ, Kränzlin B, Peters J. StAR expression and the long-term aldosterone response to high-potassium diet in Wistar-Kyoto and spontane-ously hypertensive rats.  Am J Physiol Endocrinol Metab. 2007;  292 E16-23
• 20 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.  N Engl J Med. 1999;  341 709-717
• 21 Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleinman J, Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.  N Engl J Med. 2003;  348 1309-1321
• 22 Reddy SR, Kotchen TA. Dietary sodium chloride increases blood pressure in obese Zucker rats.  Hypertension. 1992;  20 389-393
• 23 Schafer S, Linz W, Afkam F. Treatment of hypertensive nephropathy by the novel vasopeptidase inhibitor AVE7688: nephroprotection beyond ACE-.  inhibition alone. Nephrol Dial Transplant. 2003;  18 (Suppl. 4) 601
• 24 Schafer S, Linz W, Vollert H, Biemer-Daub G, Rütten H, Bleich M, Busch AE. The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy.  Diabetologia. 2004;  47 98-103
• 25 Weber KT. Aldosterone in congestive heart failure.  N Engl J Med. 2001;  345 1689-1697
• 26 Weil J, Zolk O, Griepentrog J, Wenzel U, Zimmermann WH, Eschenhagen T. Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction.  Cardiovasc Res. 2006;  69 412-422
• 27 Wotus C, Levay-Young BK, Rogers LM, Gomez-Sanchez CE, Engeland WC. Development of adrenal zonation in fetal rats defined by expression of aldosterone synthase and 11beta-hydroxylase.  Endocrinology. 1998;  , Oct 139:4397-139:4403
• 28 Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor.  Hypertension. 2005;  46 584-590

1 Both authors contributed equally

Correspondence